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Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors,
sitagliptin and saxagliptin, adjusted dosing
specification from creatinine clearance to glomerular
filtration rate, more typically reported in routine
laboratory tests. This cross-sectional study examines
all DPP-4 inhibitor initiations that require dose
adjustment and the dose selection using data from
UK general practice. Results indicate that 34% of
patients taking a nonlinagliptin DPP-4 inhibitor were
given a higher dose and 11% a lower dose than
specified in the Summary of Product Characteristics.
This reinforces the deviation from Summary of
Product Characteristics prescription of DPP-4
inhibitors identified in earlier studies despite
improvement in compatibility with routine reporting.
(Clin Ther. 2019;41:1622e1630) © 2019 The Au-
thors. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Type 2 diabetes mellitus, UK general practice.
INTRODUCTION
Dipeptidyl peptidase-4 (DPP-4) inhibitors (alogliptin,
linagliptin, saxagliptin, sitagliptin, vildagliptin) are
indicated to improve glycemic control in patients with
type 2 diabetes mellitus (T2DM). The first DPP-4
inhibitor was introduced in the United Kingdom in
2009,1 offering an additional treatment option for
patients with T2DM and renal impairment.2 According
to their Summaries of Product Characteristics (SmPCs),1622all nonlinagliptin DPP-4 inhibitors require dose
adjustment according to patients' renal function.3e6
Linagliptin is the only member of the class that does not
require dose adjustment, regardless of the degree of
renal insufficiency, because of its primarily nonrenal
mode of excretion.7,8
Until January 2018, the SmPC-specified common
upper threshold for dose adjustment for all
nonlinagliptin DPP-4 inhibitors was a creatinine
clearance (CrCl) level of 50 mL/min. Previous UK
observational studies have found that 32% of patients
with T2DM with a CrCl <50 mL/min who began
taking a nonlinagliptin DPP-4 inhibitor were taking a
higher than the SmPC-recommended dose.9 A
subsequent study also found that 14% patients with
T2DM treated with a nonlinagliptin DPP-4 inhibitor
whose renal function did not indicate dose adjustment
were treated with a lower than the SmPC-specified
dose.10 For patients with chronic kidney disease,
clinical guidelines issued by the National Institute for
Health and Care Excellence (NICE) recommend use of
the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) creatinine equation for
estimating glomerular filtration rate (GFR), an index
of kidney function.11 A possible explanation for the
discrepancy in dose selection reported in the previous
studies might be the discordance between the CrClVolume 41 Number 8
D. Spanopoulos et al.thresholds noted for dose adjustment in the SmPCs and
the estimated GFR values used in clinical practice.
In January and July 2018, respectively, the SmPCs
for sitagliptin and saxagliptin were updated to specify
a renal threshold for dose adjustment of GFR
<45 mL/min. In line with the previous studies, the
aim of this analysis was to examine dose selection in
a more recent cohort of patients with T2DM treated
with DPP-4 inhibitors after the update, adopting
variable renal threshold of GFR or CrCl, depending
on the SmPC of the relevant prescribed DPP-4
inhibitor. This study therefore will provide insights
on the extent to which the change of renal thresholds
from CrCl to GFR has improved dose selection of
DPP-4 inhibitors in UK general practice.
METHODS
PatientswithT2DMtreatedwithDPP-4 inhibitors on or
after July 15, 2018, were identified in the Clinical
Practice Research Datalink (CPRD). This date was
chosen to account for the last change on renal
adjustment specifications for a DPP-4 inhibitor. The
index prescription was the first prescription on or after
July 15, 2018, which was assessed via product codes
captured by CPRD. Patients included in the analysis
were of acceptable research standard, had a T2DM
diagnostic code before the index date, and were
registered to a general practice for 12 months, which
had to be up to standard at the time of index
prescription. Patients were at least 18 years old at
T2DM diagnosis with no history of type 1 diabetes
mellitus. Patients' renal function was estimated from
the last serum creatinine record before or at index
prescription. To account for outliers, serum creatinine
records below the first percentile and above the 99th
percentile were excluded from the analysis.
Renal function was expressed in CrCl if the index
prescription was alogliptin or vildagliptin, using the
Cockroft-Gault formula.12 Patients whose renal
function was estimated in CrCl also had at least 1
record of weight measurement to input into the
formula. Because the NICE national guidelines
recommend that clinical laboratories should report an
estimated GFR (eGFR) using the CKD-EPI
equation,13 the GFR was estimated using the CKD-
EPI formula14 for patients whose index prescription
was sitagliptin or saxagliptin. The CKD-EPI requiresAugust 2019ethnicity information for accurate estimation.
Ethnicity is poorly reported in CPRD; therefore, the
CKD-EPI equation was not adjusted for ethnicity
because the overall effect on study results is expected
to be minimal as reported in earlier studies.15
Two analytical cohorts were defined. Cohort 1
included patients with an index prescription for
saxagliptin or sitagliptin and an eGFR <45 mL/min, as
well as patients with an index prescription for
alogliptin or vildagliptin and a CrCl 50 mL/min and
<50 mL/min, respectively. Cohort 2 included patients
with an index prescription for saxagliptin or sitagliptin
and an eGFR 45 mL/min, as well as patients with an
index prescription for alogliptin and vildagliptin and a
CrCl >50 and  50 mL/min, respectively.
Cohort 1 (Higher than SmPC-Specified analysis)
Patients in cohort 1 were expected to have their dose
adjusted for the level of their renal function as
recommended in the individual SmPC for each DPP-4
inhibitor. Numbers and percentages were estimated for
patients prescribed alogliptin 25 mg, saxagliptin 5 mg,
sitagliptin 100 mg, or vildagliptin 50 mg twice daily.
In addition, patients prescribed alogliptin 12.5 mg and
sitagliptin 50 mg with more severe levels of renal
impairment (CrCl <30 mL/min and eGFR <30 mL/
min, respectively) were included in the estimates.
Cohort 2: lower than SmPC-Specified analysis
Patients in cohort 2 were expected to receive the full
dose of their DPP-4 inhibitor. Numbers and
percentages were estimated for patients prescribed
alogliptin 12.5 mg or 6.25 mg, saxagliptin 2.5 mg,
sitagliptin 50 mg or 25 mg, or vildagliptin 50 mg once
daily. Patients with a record of sulfonylurea
prescription within 30 days of vildagliptin prescription
were not included in the estimate because it is possible
that they were taking these medicines concomitantly;
this would require patients to receive a reduced
vildagliptin dose (in line with the vildagliptin SmPC).3
For class-level estimates, patients with T2DM with
linagliptin index prescription and CrCl <50 mL/min
were included in cohort 1; those with linagliptin
prescription and CrCl 50 mL/min were included in
cohort 2. These thresholds were documented in the
linagliptin SmPC to specify the threshold of moderate
renal impairment.1623
Clinical TherapeuticsThis study was approved by the Independent
Scientific Advisory Committee for Medicines and
Healthcare Products Regulatory Agency database
research (protocol 18_268R).RESULTS
A total of 18,395 patients were prescribed a DPP-4
inhibitor during the study period, of whom 17,102
(93%) met the study inclusion criteria (Appendix).
Of the 17,102 patients, 2580 patients should have
had their dosage adjusted for their level of renal
function as per the relevant SmPC (cohort 1), and
14,522 patients were expected to have received full
dosage (cohort 2). Table I gives the baseline
characteristics for all patients. Patients in cohort 1,
who by definition had a lower level of renal function,
were older, more likely to be female, and had longer
disease duration but comparable body mass index
and glycosylated hemoglobin to patients in cohort 2
(Table I).
Among patients in cohort 1, a total of 1000 were
treated with nonlinagliptin DPP-4 inhibitors and
therefore required a dose adjustment according to
SmPC recommendations. However, 336 (33.6%)
were treated with a higher than the SmPC-specified
dose. In cohort 1, a total of 45 of 160 patientsTable I. Baseline characteristics of the study patients.a
Characteristic
(n ¼




BMI at index, kg/m2 31.
HbA1c before index, % of total hemoglobin 8.
GFR before or at index, mL/min 36.
CrCl before or at index, mL/min 38.
Disease duration, mo 34
Abbreviations: BMI ¼ body mass index; CrCl ¼ creatinine clearan
hemoglobin.
a Data are presented as mean (SD). Numbers do not total becau
1624(28.1%) treated with saxagliptin and 172 of 526
patients (32.7%) treated with sitagliptin were taking
a higher than SmPC-specified dosage. In addition,
116 of 298 patients (38.9%) treated with alogliptin
and 3 of 16 patients (19%) treated with vildagliptin
were taking a higher than SmPC-specified dosage
(Table II). Of the 14,522 patients in cohort 2, a total
of 11,411 were treated with a nonlinagliptin DPP-4
inhibitor, of whom 1296 (11.4%) were taking a
lower than SmPC-specified dosage. In cohort 2, the
proportion of patients prescribed saxagliptin and
sitagliptin who were taking a lower than SmPC-
specified dose was similar to the class mean (10.2%
and 11.3%, respectively). Furthermore, in cohort 2, a
total of 358 of 3067 patients (12%) treated with
alogliptin and 19 of 95 patients (20%) treated with
vildagliptin were taking a lower than SmPC-specified
dosage.
Information regarding higher than SmPC-specified
dose with nonlinagliptin DPP-4 inhibitors in patients
with renal impairment is limited. However,
regulators provide guidance on dosing for all
nonlinagliptin DPP-4 inhibitors for patients with
renal impairment in their respective SmPCs because
of increased systemic drug exposure with increasing






9 (12.0) 79.9 (7.9) 65.7 (11.3)
3 (59.0) 1274 (49.4) 8819 (60.7)
9 (41.0) 1306 (50.6) 5703 (39.3)
2 (5.9) 29.0 (5.2) 31.6 (5.9)
0 (1.6) 8.1 (1.5) 8.1 (1.5)
3 (10.4) 79.7 (18.6) 73.1 (23.5)
3 (9.8) 102.3 (40.3) 92.7 (43.8)
7 (213) 300 (194) 307 (198)
ce; GFR ¼ glomerular filtration rate; HbA1c ¼ glycosylated
se of missing data.
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Table II. DPP-4 inhibitor dose selection based on SmPC renal thresholds.
DPP-4 Inhibitor Cohort 1 (n ¼ 2580) Cohort 2 (n ¼ 14,522)
Total No. No. (%) Higher Than
SmPC Specified
Total No. No. (%) Lower Than
SmPC Specified
Alogliptin 298 116 (38.9) 3067 358 (11.7)
Linagliptin 1580 NA 3081 NA
Saxagliptin 160 45 (28.1) 1415 145 (10.2)
Sitagliptin 526 172 (32.7) 6864 774 (11.3)
Vildagliptin 16 3 (18.8) 95 19 (20.0)
All DPP-4 inhibitors 2580 336 (13.0) 14,522 1296 (8.9)
All DPP-4 inhibitors excluding
linagliptin
1000 336 (33.6) 11,411 1296 (11.4)
Abbreviations: DPP-4 ¼ dipeptidyl peptidase-4; NA ¼ not applicable; SmPC ¼ Summary of Product Characteristics.
D. Spanopoulos et al.lower than SmPC-specified dose with nonlinagliptin
DPP-4 inhibitors is also limited, but reduced
plasma concentrations may lead to altered
pharmacodynamic properties and therapeutic
efficacy.CONCLUSIONS
In addition to previous studies,9,10 this study provides
further evidence on DPP-4 inhibitor dose selection in
relation to newly defined renal thresholds for 2
members of the class. Of all patients with diabetes
taking nonlinagliptin DDP-4 inhibitors who required
dose adjustment, 33.6% were prescribed a DPP-4
inhibitor at a higher dose than specified in the SmPC.
Furthermore, 11.4% of patients who did not require
dose adjustment were prescribed a lower dose than
specified in the SmPC. For saxagliptin and sitagliptin,
the 2 DPP-4 inhibitors that recently updated the dose
adjustment thresholds recommended in their SmPC
from CrCl to GFR, 28.1% and 32.7% of patients
were taking a higher than SmPC-specified dosage,
whereas 10.2% and 11.3% were taking lower than
SmPC-specified dosage, respectively. Despite changes
in measures that are more compatible with
laboratory results, prescription of DPP-4 inhibitors at
doses outside those recommended in the SmPC is stillAugust 2019common in general practice. We recommend that
clinicians are given further education on dose
adjustment of DPP-4 inhibitors in patients with
T2DM and renal impairment.FUNDING SOURCES
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1626APPENDIX 1. PATIENT FLOW DIAGRAM.1 diabetes mellitus; T2DM, type 2 diabetes mellitus;
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D. Spanopoulos et al.Appendix II. Product codes for DPP-4 inhibitors.Prodcode Product Name
Alogliptin
59809 Alogliptin 6.25mg tablets
60328 Alogliptin 12.5mg tablets
59177 Alogliptin 25mg tablets
60682 Vipidia 25mg tablets
60681 Vipidia 12.5mg tablets
62326 Vipidia 6.25mg tablets
Linagliptin
46665 Linagliptin 5mg tablets
46716 Trajenta 5mg tablets
Saxagliptin
41204 Saxagliptin 5mg tablets
45775 Saxagliptin 2.5mg tablets
41431 Onglyza 5mg tablets
45821 Onglyza 2.5mg tablets
Sitagliptin
35022 Sitagliptin 100mg tablets
48401 Sitagliptin 50mg tablets
48533 Sitagliptin 25mg tablets
35462 Januvia 100mg tablets
50087 Januvia 50mg tablets
50124 Januvia 25mg tablets
Vildagliptin
37875 Vildagliptin 50mg tabletsAppendix III. Medical codes for T2DMMedcode Read Code Read Term
758 C10F.00 Type 2 diabetes mellitus
506 C100112 Non-insulin dependent diabetes mellitus
4513 C109.00 Non-insulin dependent diabetes mellitus
17859 C109.12 Type 2 diabetes mellitus
1407 C10FJ00 Insulin treated Type 2 diabetes mellitus
18219 C109.13 Type II diabetes mellitus
18390 C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria
5884 C109.11 NIDDM - Non-insulin dependent diabetes mellitus
18278 C109J00 Insulin treated Type 2 diabetes mellitus
(continued on next page)
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Appendix III. (Continued)
Medcode Read Code Read Term
26054 C10FL00 Type 2 diabetes mellitus with persistent proteinuria
12640 C10FC00 Type 2 diabetes mellitus with nephropathy
22884 C10F.11 Type II diabetes mellitus
18496 C10F600 Type 2 diabetes mellitus with retinopathy
8403 C109700 Non-insulin dependant diabetes mellitus - poor control
25627 C10F700 Type 2 diabetes mellitus - poor control
32627 C10FN00 Type 2 diabetes mellitus with ketoacidosis
34912 C109400 Non-insulin dependent diabetes mellitus with ulcer
47954 C10F900 Type 2 diabetes mellitus without complication
34450 C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus
36695 C10D.00 Diabetes mellitus autosomal dominant type 2
29979 C109900 Non-insulin-dependent diabetes mellitus without complication
34268 C10F200 Type 2 diabetes mellitus with neurological complications
53392 C10F911 Type II diabetes mellitus without complication
18777 C10F000 Type 2 diabetes mellitus with kidney complications
35385 C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy
25591 C10FQ00 Type 2 diabetes mellitus with exudative maculopathy
17262 C109600 Non-insulin-dependent diabetes mellitus with retinopathy
18425 C10FB00 Type 2 diabetes mellitus with polyneuropathy
60796 C10FL11 Type II diabetes mellitus with persistent proteinuria
49074 C10F400 Type 2 diabetes mellitus with ulcer
41389 C105100 Diabetes mellitus, adult onset, + ophthalmic manifestation
63762 C10z100 Diabetes mellitus, adult onset, + unspecified complication
44982 C10FE00 Type 2 diabetes mellitus with diabetic cataract
50609 L180600 Pre-existing diabetes mellitus, non-insulin-dependent
59365 C109C00 Non-insulin dependent diabetes mellitus with nephropathy
46917 C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma
47321 C10F100 Type 2 diabetes mellitus with ophthalmic complications
62674 C10FA00 Type 2 diabetes mellitus with mononeuropathy
47315 C10F711 Type II diabetes mellitus - poor control
18264 C109J12 Insulin treated Type II diabetes mellitus
24458 C109711 Type II diabetes mellitus - poor control
12736 C10F500 Type 2 diabetes mellitus with gangrene
36633 C109K00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus
63690 C10FR00 Type 2 diabetes mellitus with gastroparesis
64668 C10FJ11 Insulin treated Type II diabetes mellitus
45913 C109712 Type 2 diabetes mellitus - poor control
51756 C10FP00 Type 2 diabetes mellitus with ketoacidotic coma
58604 C109611 Type II diabetes mellitus with retinopathy
49655 C10F611 Type II diabetes mellitus with retinopathy
37806 C10FF00 Type 2 diabetes mellitus with peripheral angiopathy
59253 C10FG00 Type 2 diabetes mellitus with arthropathy
37648 C109J11 Insulin treated non-insulin dependent diabetes mellitus
55075 C109411 Type II diabetes mellitus with ulcer
Clinical Therapeutics
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Appendix III. (Continued)
Medcode Read Code Read Term
52303 C109000 Non-insulin-dependent diabetes mellitus with kidney comps
42762 C109612 Type 2 diabetes mellitus with retinopathy
24836 C109C12 Type 2 diabetes mellitus with nephropathy
45467 C109B00 Non-insulin dependent diabetes mellitus with polyneuropathy
45919 C109212 Type 2 diabetes mellitus with neurological complications
50429 C109100 Non-insulin-dependent diabetes mellitus with ophthalm comps
69278 C109E00 Non-insulin depend diabetes mellitus with diabetic cataract
40401 C109500 Non-insulin dependent diabetes mellitus with gangrene
43785 C109D00 Non-insulin dependent diabetes mellitus with hypoglyca coma
44779 C109E12 Type 2 diabetes mellitus with diabetic cataract
47816 C109H11 Type II diabetes mellitus with neuropathic arthropathy
55842 C109200 Non-insulin-dependent diabetes mellitus with neuro comps
18209 C109012 Type 2 diabetes mellitus with kidney complications
48192 C109E11 Type II diabetes mellitus with diabetic cataract
50225 C109011 Type II diabetes mellitus with kidney complications
62107 C109511 Type II diabetes mellitus with gangrene
65267 C10F300 Type 2 diabetes mellitus with multiple complications
65704 C109412 Type 2 diabetes mellitus with ulcer
43227 C10F311 Type II diabetes mellitus with multiple complications
46150 C109512 Type 2 diabetes mellitus with gangrene
64571 C109C11 Type II diabetes mellitus with nephropathy
66965 C109H12 Type 2 diabetes mellitus with neuropathic arthropathy
24693 C109G00 Non-insulin dependent diabetes mellitus with arthropathy
54899 C109F11 Type II diabetes mellitus with peripheral angiopathy
61071 C109D12 Type 2 diabetes mellitus with hypoglycaemic coma
67905 C109211 Type II diabetes mellitus with neurological complications
47409 C109B11 Type II diabetes mellitus with polyneuropathy
50527 C10FB11 Type II diabetes mellitus with polyneuropathy
57278 C10F011 Type II diabetes mellitus with kidney complications
59725 C109111 Type II diabetes mellitus with ophthalmic complications
60699 C109F12 Type 2 diabetes mellitus with peripheral angiopathy
62146 C109300 Non-insulin-dependent diabetes mellitus with multiple comps
72320 C109A00 Non-insulin dependent diabetes mellitus with mononeuropathy
18143 C109G11 Type II diabetes mellitus with arthropathy
49869 C109G12 Type 2 diabetes mellitus with arthropathy
50813 C109A11 Type II diabetes mellitus with mononeuropathy
56268 C109D11 Type II diabetes mellitus with hypoglycaemic coma
70316 C109112 Type 2 diabetes mellitus with ophthalmic complications
85991 C10FM11 Type II diabetes mellitus with persistent microalbuminuria
91646 C10F411 Type II diabetes mellitus with ulcer
93727 C10FE11 Type II diabetes mellitus with diabetic cataract
D. Spanopoulos et al.
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